NurOwn, or autologous mesenchymal stromal cells secreting neurotrophic factors cells (MSC-NTF), has shown promise as an approach to neurodegenerative disorders. These autologous MSC-NTF cells are designed to effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression.
In March 2021, following a review of the pivotal phase 3 study (NCT03280056) of NurOwn, the FDA concluded that the current level of data did not cross the threshold of substantial evidence to support a BLA. All told, NurOwn did not meet its primary end point of statistical significance, as 33% and 28% of those on MSC-NTF and placebo, respectively, showed a change in disease progression of at least 1.25 points on ASL Functional Rating Scale-Revised (ALSFRS-R) after 28 weeks of treatment.2
Real-World Italian Survey Study Provides Insight on SMA Prevalence in Age of New Therapeutics
High rates of treatment use were observed across all types of spinal muscular atrophy, with nusinersen, the first approved disease-modifying treatment, as the most commonly used.
Despite not meeting its primary end point, the therapy did show positive effects in those with less severe forms of ALS, characterized by baseline ALSFRS-R scores of at least 35. In that prespecified analysis, 35% of those on NurOwn had a clinical response vs 16% of those on placebo (odds ratio [OR], 2.6; P = .29). On secondary end points, the newly added results indicated that MSC-NTF participants progressed on average 2 points less on the ALSFRS-R compared with placebo (P = .05), while for participants with more advanced disease, the change from baseline to week 28 was similar between treatment groups (P = .97).3
In post hoc analyses, it was originally reported that the least square (LS) mean for placebo (range, –4.32 to –5.81) exhibited far less spread in the LS mean change than those in the MSC-NFT group (range, –1.58 to –4.61). These LS means were corrected for both the MSC-NTF (range, –1.39 to –4.82) and placebo (range, –4.24 to –5.98), but still indicated that placebo-treated patients lost 4 to 5 points on average in 28 weeks across baseline thresholds while those on active treatment lost less function at higher compared with lower baseline levels.
REFERENCES
1. BrainStorm Cell Therapeutics submits Type A meeting request to US Food and Drug Adminstration. News release. BrainStorm Cell Therapeutics. December 12, 2022. Accessed December 13, 2022. https://www.prnewswire.com/il/news-releases/brainstorm-cell-therapeutics-submits-type-a-meeting-request-to-us-food-and-drug-administration-301700042.html
2. Cudkowicz ME, Lindborg SR, Goyal NA, et al. A randomized placebo-controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis. Muscle & Nerve. Published online December 10, 2021. doi:10.1002/mus.27472
3. Erratum. Muscle & Nerve. Published online August 12, 2022. doi:10.1002/mus.27697